Citations

Clear

1727 citation(s) found for "Fu, Alan".

An International Data Set for the Study of Chronic Myelomonocytic Leukemia (CMML) Validates Modern Prognostic Scoring Systems and Demonstrates a Critical Need for Novel Prognostication Strategies
Padron, Eric , Garcia‐Manero, Guillermo , Patnaik, Mrinal M. , Lasho, Terra, Nazha, Aziz , Rampal, Raajit K. , Sanchez, Matias , Ali, Najla H. Al, Thompson, Zachary , Fenaux, Pierre , Killick, Sally , Tefferi, Ayalew , Itzykson, Raphaël , Lasho, Terra, Jabbour, Elias , Lee, Ji‐Hyun , Colla, Simona , Kantarjian, Hagop M. , Sekeres, Mikkael A. , List, Alan F. , Onida, Francesco , Komrokji, Rami S. , Solary, Éric

Mayo Clinic

Blood | October 10, 2019 | Volume: 124 | Issue: 21 | Pages: 530-530

10.1182/blood.v124.21.530.530 Get It

Abstract Introduction: CMML is a heterogeneous malignancy characterized by peripheral monocytosis and a propensity for AML transformation. Given the low incidence of CMML and its broad range complexity, a large disease-specific data set is necessary to discern independent co-variates predictive of disease behavior. Several prognostic models derived from smaller data sets have been developed to stratify CMML patients into distinct groups that are predictive for OS. However, the validity of these models in a large international data set has never been investigated. Here, we present the largest International CMML data base established to date and report key baseline characteristics predictive for disease outcome. We externally validate and perform a detailed statistical comparison between the International Prognostic Scoring System (IPSS), Revised (R)-IPSS, Global MD Anderson Scoring System (MDASC), MD Anderson Prognostic Score (MDAPS), Dusseldorf Score (DS), Mayo, and Spanish Scoring Systems (CPSS). Methods: Data were abstracted by each contributing institution and deposited for central data review at the Moffitt Cancer Center. Manual review of cases was performed to ensure data quality prior to analysis. Only WHO defined CMML was included. The primary objective of this study was to establish an international CMML data set and validate the above models calculated at the time of presentation to each center. All prognostic models were calculated as previously described. The Kaplan–Meier (KM) method was used to estimate median OS and the log rank test was used to compare KM survival estimates with SPSS version 21.0. Random Forest Survival (RSF) and ROC analysis was done with R. Results: Between July 1981 and June 2014, 1832 CMML patients were captured in the International CMML database. Median age at diagnosis was 70 (16-93) years with a male (67%) predominance. By the WHO classification, the majority of patients had CMML-1 (79.9% vs. 20.1%) and most patients were evenly subcategorized as MPN-CMML (49.8%) versus MDS-CMML (50.2%) by FAB criteria. Splenomegaly was demonstrable in 25%. Most patients had favorable cytogenetics by both IPSS (70%) and CPSS (67.6%) classification schemas. Mean BM blast % was 5.6 and mean monocyte count was 4.85x103/dL. Median OS of the entire data set was 31.6 months. All tested prognostic models were valid and able to predict OS (p<0.0001). To compare relative model performance, 1013 complete cases with sufficient data to calculate all risk models were compared using time dependent receiver operator characteristic (ROC) curves and their area under the curves (AUC). ROC curves were calculated for OS at 36 months. The R-IPSS model had the highest AUC (0.694) while the DS model had the lowest (0.635). The difference in AUC between the R-IPSS and DS models was statistically significant (p = 0.003) whereas there was no significant difference from other models tested. To determine which models were most vulnerable to reclassification from low-risk to higher risk, we calculated a vulnerability score defined by the number of models able to up-stage low-risk disease in more than 15% of cases. Using this metric, the Mayo and MDASC scores were least vulnerable to up-staging by other models. Lastly, we used an orthogonal method for determination of variable importance (RSF for OS at 36 months). RSF is an ensemble method of classification and regression tree methodology. Ranking of variables by their weighted importance determined by this procedure identified the top five variables were hemoglobin, circulating blasts, platelet count, number of cytopenias, and karyotype. A new risk model was developed using the results of the RSF with an AUC of 0.720, which was comparable but not significantly different than other modern scoring systems. Conclusions: This represents the largest international CMML-specific data set derived from eight unique centers of excellence. All modern prognostic models were valid and performed comparably. Despite novel strategies for variable importance discovery, an improved model could not be constructed. This data suggest that the power of clinical variables has reached an asymptote and highlights the need for incorporation of molecular and other novel biological features. This data set is currently being populated with molecular data and is being leveraged to test published CMML molecular prognostic models which will be disclosed at the time of presentation. Disclosures Garcia-Manero: Epizyme, Inc: Research Funding. Fenaux:Celgene, Janssenm, Novartis: Research Funding. Kantarjian:ARIAD, Pfizer, Amgen: Research Funding. Sekeres:Celgene: Membership on an entity's Board of Directors or advisory committees; Amgen Corp: Membership on an entity's Board of Directors or advisory committees; Boehringer-Ingelheim Corp: Membership on an entity's Board of Directors or advisory committees.
The Mayo Clinic Experience with 66 Patients with Type II Cryoglobulinemia.
Kyle, Robert A. , Lacy, Martha Q. , Bryce, Alan H. , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

Blood | October 10, 2019 | Volume: 104 | Issue: 11 | Pages: 1493-1493

10.1182/blood.v104.11.1493.1493 Get It

Abstract Background: Cryoglobulinemia(CG) is a relatively uncommon disorder which has been recognized as a syndrome for nearly forty years. The further classification into types I, II, and III was established thirty years ago, with Type II consisting of a monoclonal immunoglobulin possessing activity towards a polyclonal component. In the interim, many disease associations have been described and various therapies tried, but clinical trials remain rare, and the natural history, causes, and pathways of CG require further investigation. Methods: We examined the records of all patients seen at the Mayo Clinic, Rochester, with Type II CG between 3/2/1994 and 11/27/2000 using a prospectively held dysproteinemia database. Results: Of 66 total patients 30 were male(45%) and 36 were female(55%) with mean ages of 52.7±11.0 and 60.9±12.6, respectively. 63 patients were Caucasian, with one each of African, Hispanic, and other. 34 patients(52%) presented with purpura, 16 with edema(24%), 12 with neuropathy(18%), 12 with fatigue, 10 with arthralgia(15%), 8 with weight loss(12%), 5 with livido reticularis(8%), 4 with leg ulcers(6%), and 2 with infarcted extremities(2%). Of our patients, 13 had Type II CG (20%) unassociated with infection or lymphoma. 38 patients(58%) had hepatitis C(HCV), of whom 12 underwent genotyping with 10 having genotype 1a or 1b and 2 having genotype 2a or 2b. No patients had isolated Hepatitis B(HBV) though 8 HCV patients were coinfected with HBV. One patient each had CMV and EBV. 7 patients(10%) had Sjogren’s disease, and 1 had scleroderma. 11 patients (17%) had a lymphoproliferative disorder (LPD), and 5 more went on to develop LPD. Of these, 7 patients had a B-cell LPD, 4 had a MALT lymphoma, 4 had a non specific LPD, one had a lymphoplasmacytic lymphoma, and one had Gaucher’s thrombocytopenia. Significant renal disease developed in 23 patients(35%), with 12 being membranoproliferative glomerulonephritis (18%) and 3 being mesangioproliferative glomerulonephritis. Pertinent laboratory finding included a mean cryocrit of 7.6%±12.5, a positive rheumatoid factor in 36 out of 36, and hypocomplementemia in 33 of 41(80%). Liver function testing was reflective of the patient’s hepatitis status. Serum electrophoresis in 48 patients revealed the following patterns: 22 were normal(46%), 15 had a γ peak(31%), 5 polyclonal patterns(10%), 5 hypogammaglobulinemia, and one a β-γ peak. Of 32 samples where a monoclonal antibody was isolated 29 were IgM (91%), and 3 IgG (9%). The light chains were 88% κ, with 12% λ. Treatment was generally guided by the comorbidities, and many (30%) required no specific treatment for Type II CG. In the 38 HCV patients, 17 received interferon with or without ribavirin and 18 were deemed not to need treatment, while 2 received steroids alone and 1 was lost to follow up. In 28 patients without HCV 20 received steroids(71%), while 5 received other treatments and 3 were untreated. Of 46 patients who received any treatment, 27 (59%) achieved no response or had disease progression and required a change in therapy. To date, 8 patients have died, with none of deaths specifically attributable to complications of cryoglobulinemia. Conclusion: Type II CG is a non fatal disease most frequently associated with HCV. Optimal disease specific treatment is as yet undefined, and is generally directed at the underlying comorbidity when possible. Not all cases require treatment and many can be followed symptomatically.
Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates
Nguyen, David‐Dan , Barber, Neil , Bidair, Mo, Gilling, Peter , Anderson, Paul , Zorn, Kevin C. , Badlani, Gopal , Humphreys, Mitch, Kaplan, Steven A. , Kaufman, Ronald P., So, Alan , Paterson, Ryan F. , Goldenberg, Larry , Elterman, Dean , Desai, Mihir , Lingeman, J.E., Roehrborn, Claus G. , Bhojani, Naeem , Bidair, Mohamed

Mayo Clinic

BJU International | October 9, 2019 | Volume: 125 | Issue: 1 | Pages: 112-122

10.1111/bju.14917 | PMID 31599044 Get It

Objective To compare the outcomes of Aquablation in 30–80 mL prostates with those in 80–150 mL prostates. Surgical options, especially with short learning curves, are limited when treating large prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation (AquaBeam System, PROCEPT BioRobotics Inc., Redwood City, CA, USA) could solve this issue with global reproducibility, independent of prostate volume. Patients and Methods Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue (WATER [W‐I]; NCT02505919) is a prospective, double‐blind, multicentre, international clinical trial comparing Aquablation and transurethral resection of the prostate (TURP) for the treatment of LUTS/BPH in prostates between 30 and 80 mL. WATER II (W‐II; NCT03123250) is a prospective, multicentre, single‐arm international clinical trial of Aquablation in prostates between 80 and 150 mL. We compare baseline parameters and 12‐month outcomes in 116 W‐I and 101 W‐II study patients. Students’ t ‐test or Wilcoxon tests were used for continuous variables and Fisher’s test for binary variables. Results The mean (SD) operative time was 33 (17) and 37 (13) min in W‐I and W‐II, respectively. Actual treatment time was 4 and 8 min in W‐I and W‐II, respectively. The mean change in the International Prostate Symptom Score was substantial averaging (at 12 months) 15.1 in W‐I and 17.1 in W‐II ( P = 0.605). By 3 months, Clavien–Dindo grade ≥II events occurred in 19.8% of W‐I patients and 34.7% of W‐II patients ( P = 0.468). Conclusion Aquablation clinically normalises outcomes between patients with 30–80 mL prostates and patients with 80–150 mL prostates treated for LUTS/BPH, with an expected increase in the risk of complications in larger prostates. Long‐term outcomes of procedure durability are needed.
1247 Development of a Patient Reported Outcome (PRO) Questionnaire to Assess the Symptoms of Eosinophilic Gastritis and Gastroenteritis (EG/EGE-SQ©)
Hirano, Ikuo , Banderas, Benjamin , Woolley, J. Michael, Ollis, Sarah , Love, Emily, Shields, Alan L. , Shaw, Camilla, Rasmussen, Henrik , Dellon, Evan S. , Murray, Joseph A. , Peterson, Kathryn A. , Foley, Catherine

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S694-S695

10.14309/01.ajg.0000594516.37251.84 Get It

INTRODUCTION: Patients with eosinophilic gastritis and/or gastroenteritis (EG/EGE) experience significantly reduced health-related quality of life related to the symptoms and signs of their disease. There is a need to develop a PRO questionnaire for clinical research in EG/EGE. The objectives of this study were to develop a symptom questionnaire (drafted using literature and clinician input to determine preliminary measurement concepts) and then (1) identify, describe, and substantiate signs, symptoms, and impacts of EG/EGE from the perspective of adults with the condition via concept elicitation methods; and (2) evaluate the properties of the questionnaire and make modifications via cognitive debriefing methods. METHODS: Interviews were conducted, transcribed, coded, and analyzed. Eligible adults with EG/EGE first participated in a concept elicitation segment where they described their experiences with EG/EGE, continuing until saturation was achieved, adding symptoms to the draft symptom questionnaire as needed. This was followed by a cognitive debrief to assess the appropriateness of the draft symptom questionnaire, where patients assessed readability, comprehensibility, relevance, and comprehensiveness. The questionnaire was modified based on patient feedback, then re-evaluated to confirm its appropriateness. RESULTS: In total, 16 interviews were conducted and 24 signs and symptoms were reported during concept elicitation. The most frequently reported (Figure 1) were abdominal pain, nausea, diarrhea, vomiting, and abdominal cramping; while abdominal pain, nausea, and diarrhea were the most bothersome to patients. Saturation was achieved after 12 interviews. In the cognitive debriefing, revisions included the addition of a vomiting frequency item and revision of the early satiety item for clarity. Response options were modified to instruct the participants to assess each symptom “at its worst”. For the final version of the EG/EGE-SQ©, participants were able to read, comprehend, and provide appropriate responses, and reported that the resulting questionnaire was comprehensive for their condition. CONCLUSION: The results of this research support the content validity, including comprehensiveness and interpretability, of the EG/EGE-SQ© which offers the potential for use in clinical research to assess symptoms in patients with EG/EGE. Future research is needed to assess its psychometric properties including reliability and validity, responsiveness, and potential for use in pediatric populations.
1244 Symptomatic Patients Suspected of Eosinophilic Gastritis and/or Enteritis Have Elevated Mucosal Mast Cell Counts Without Eosinophilia: A New Diagnostic Entity?
Chehade, Mirna , Khoury, Paneez , Leung, John , Bledsoe, Adam C. , Shaw, Camilla, Rasmussen, Henrik , Singh, Bhupinder , Chang, Alan T., Youngblood, Bradford A. , Kamboj, Amol P. , Hirano, Ikuo , Murray, Joseph A. , Dellon, Evan S. , Peterson, Kathryn A. , Falk, Gary W. , Genta, Robert M. , Gonsalves, Nirmala , Rothenberg, Marc E.

Mayo Clinic

American Journal of Gastroenterology | October 8, 2019 | Volume: 114 | Issue: 1 | Pages: S693-S694

10.14309/01.ajg.0000594504.91508.61 Get It

INTRODUCTION: Eosinophilic gastrointestinal diseases (EGIDs) are a set of inflammatory diseases subclassified according to the site(s) of abnormal accumulation of eosinophils (eos) in the gastrointestinal (GI) tract such as eosinophilic esophagitis (EoE), gastroenteritis (EGE), and colitis. These conditions often decrease quality of life due to debilitating symptoms. While the pathogenesis of EGIDs is primarily thought to be driven by eos, there is increasing evidence for the involvement of mast cells (MCs). AIM: To characterize symptomatic patients (pts) with suspected EG/EGE who did not meet histopathologic entry criteria for mucosal eosinophilia for a Phase 2 randomized, double-blind, placebo-controlled study of AK002, an anti-Siglec-8 antibody. METHODS: To undergo screening endoscopy for this study, pts were required to report an average symptom score ≥3 (0 to 10 scale) for abdominal pain, nausea, and/or diarrhea on a daily patient-reported outcome questionnaire for ≥2 weeks and have no other known cause for GI symptoms. During the screening endoscopy, biopsies were systematically obtained from the stomach and duodenum, and read by a single pathologist. Eos counts (eos/hpf; hpf area = 0.237 mm 2 ) were assessed on H&E slides. To quantify MCs, immunohistochemistry for tryptase was performed. We quantified eos and MCs in the stomach and duodenum. Histopathologic entry criteria for the randomized study was ≥30 eos/hpf in 5 hpfs in the stomach (EG) and/or ≥30 eos/hpf in 3 hpfs in the duodenum (EGE). A literature review was conducted to determine normal MC counts in the GI tract. RESULTS: Eighty-eight pts underwent screening endoscopy based upon suspected EG/EGE and active symptoms, and 72 pts met histopathologic eos criteria. All pts whose eos did not meet entry criteria (n = 16) were found to have elevated MC counts (Figure 1; reported normal range = 12-19 MCs/hpf). In these pts, the mean gastric eos count was 6 eos/hpf in 5 hpfs and mean duodenal eos count was 15 eos/hpf in 3 hpfs. In contrast, these pts exhibited a mean gastric MC count of 47 MC/hpf in 5 hpfs and a mean duodenal MC count of 49 MC/hpf in 3 hpfs. Almost all symptomatic pts screened (87/88; 99%) had elevated MC counts. CONCLUSION: Data from this large randomized EG/EGE study showed that symptomatic pts with suspected EG/EGE had increased mucosal MCs with or without mucosal eosinophilia. These data suggest that MCs may play a role in pts with suspected EG/EGE and raise the possibility of a unique clinical presentation driven by MCs.
Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Riba, Michelle B., Donovan, Kristine A. , Andersen, Barbara L. , Braun, IIana, Breitbart, William , Brewer, Benjamin W. , Buchmann, Luke, Clark, Matthew M. , Collins, Molly, Corbett, Cheyenne , Fleishman, Stewart B., Garcia, Sofia F. , Greenberg, Donna, Handzo, Rev. George F., Hoofring, Laura, Huang, Chao‐Hui , Martin, Sara , McGuffey, Lisa, Mitchell, William M. , Morrison, Laura , Pailler, Megan E. , Parnes, Francine, Pazar, Janice P., Ralston, Laurel, Salman, Jaroslava, Shannon-Dudley, Moreen, Valentine, Alan , McMillian, Nicole R., Darlow, Susan, Garcia, Sofia F , Handzo, Rev. George F., Lally, Robin Mary , Mitchell, William, Palesh, Oxana Gronskaya

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 7, 2019 | Volume: 17 | Issue: 10 | Pages: 1229-1249

10.6004/jnccn.2019.0048 | PMID 31590149 Get It

Distress is defined in the NCCN Guidelines for Distress Management as a multifactorial, unpleasant experience of a psychologic (ie, cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere with the ability to cope effectively with cancer, its physical symptoms, and its treatment. Early evaluation and screening for distress leads to early and timely management of psychologic distress, which in turn improves medical management. The panel for the Distress Management Guidelines recently added a new principles section including guidance on implementation of standards of psychosocial care for patients with cancer.
Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction
Cameron, Alan C. , Lang, Ninian N. , Chugh, Atul, Floras, John S. , Taler, Sandra J. , Delles, Christian , Lang, Ninian N , Dominiczak, Anna F. , Jennings, Garry , Batlle, Daniel , Bursztyn, Michael , Touyz, Rhian M. , Cameron, Alan C

Mayo Clinic

Hypertension | October 7, 2019 | Volume: 74 | Issue: 6 | Pages: 1216-1225

10.1161/hypertensionaha.119.13343 | PMID 31587571 Get It

Cervicocerebral quantitative arterial tortuosity: a biomarker of arteriopathy in children with intracranial aneurysms
Chen, Alan M., Karani, Kunal B. , Taylor, J. Michael , Zhang, Bin , Furthmiller, Andrew , Vela, Gabriel De, Leach, James L. , Vadivelu, Sudhakar , Abruzzo, Todd , Abruzzo, Todd A

Mayo Clinic

Journal of Neurosurgery: Pediatrics | October 4, 2019 | Volume: 24 | Issue: 4 | Pages: 389-396

10.3171/2019.5.peds1982 | PMID 31349231 Get It

OBJECTIVEAlthough intracranial arterial aneurysms (IAAs) of childhood are usually idiopathic, it is possible that underlying arteriopathy escapes detection when using conventional diagnostic tools. Quantitative arterial tortuosity (QAT) has been studied as a biomarker of arteriopathy. The authors analyzed cervicocerebral QAT in children with idiopathic IAAs to assess the possibility of arteriopathy.METHODSCases were identified by text-string searches of imaging reports spanning the period January 1993 through June 2017. QAT of cervicocerebral arterial segments was measured from cross-sectional studies using image-processing software. Other imaging and clinical data were confirmed by retrospective electronic record review. Children with idiopathic IAAs and positive case controls, with congenital arteriopathy differentiated according to aneurysm status (with and without an aneurysm), were compared to each other and to healthy controls without vascular risk factors.RESULTSCervicocerebral QAT was measured in 314 children: 24 with idiopathic IAAs, 163 with congenital arteriopathy (including 14 arteriopathic IAAs), and 127 healthy controls. QAT of all vertebrobasilar segments was larger in children with IAAs (idiopathic and arteriopathic forms) (p < 0.05). In children with congenital arteriopathy without an aneurysm, QAT was decreased for the distal cervical vertebral arteries and increased for the supraspinal vertebral artery relative to healthy children. QAT of specific cervicocerebral segments correlated with IAA size and rupture status.CONCLUSIONSCervicocerebral QAT is a biomarker of arteriopathy in children with IAA, even in the absence of other disease markers. Additional findings suggest a correlation of cervicocerebral QAT with IAA size and rupture status and with the presence of IAA in children with congenital arteriopathy.
Pediatric neurosurgeons’ views regarding prenatal surgery for myelomeningocele and the management of hydrocephalus: a national survey
Riley, John S. , Antiel, Ryan M. , Flake, Alan W. , Rintoul, Natalie E. , Lantos, John D. , Traynor, Michael D. , Adzick, N. Scott , Heuer, Gregory G. , Johnson, Mark Paul , Feudtner, Chris

Mayo Clinic

Neurosurgical Focus | October 4, 2019 | Volume: 47 | Issue: 4 | Pages: E8

10.3171/2019.7.focus19406 | PMID 31574481 Get It

OBJECTIVE The Management of Myelomeningocele Study (MOMS) compared prenatal with postnatal surgery for myelomeningocele (MMC). The present study sought to determine how MOMS influenced the clinical recommendations of pediatric neurosurgeons, how surgeons’ risk tolerance affected their views, how their views compare to those of their colleagues in other specialties, and how their management of hydrocephalus compares to the guidelines used in the MOMS trial. METHODS A cross-sectional survey was sent to all 154 pediatric neurosurgeons in the American Society of Pediatric Neurosurgeons. The effect of surgeons’ risk tolerance on opinions and counseling of prenatal closure was determined by using ordered logistic regression. RESULTS Compared to postnatal closure, 71% of responding pediatric neurosurgeons viewed prenatal closure as either “very favorable” or “somewhat favorable,” and 51% reported being more likely to recommend prenatal surgery in light of MOMS. Compared to pediatric surgeons, neonatologists, and maternal-fetal medicine specialists, pediatric neurosurgeons viewed prenatal MMC repair less favorably (p < 0.001). Responders who believed the surgical risks were high were less likely to view prenatal surgery favorably and were also less likely to recommend prenatal surgery (p < 0.001). The management of hydrocephalus was variable, with 60% of responders using endoscopic third ventriculostomy in addition to ventriculoperitoneal shunts. CONCLUSIONS The majority of pediatric neurosurgeons have a favorable view of prenatal surgery for MMC following MOMS, although less so than in other specialties. The reported acceptability of surgical risks was strongly predictive of prenatal counseling. Variation in the management of hydrocephalus may impact outcomes following prenatal closure.
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
Fitzmaurice, Christina , Abate, Degu , Abbasi, Naghmeh , Abbastabar, Hedayat , Abdelalim, Ahmed , Abdoli, Amir , Abdulle, Abdishakur S. M., Abebe, Nebiyu Dereje , Abraha, Haftom Niguse , Abualhasan, Ahmed , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Afarideh, Mohsen , Afshari, Mahdi , Aghaali, Mohammad , Agius, Dominic, Agrawal, Sutapa , Ahmadi, Ayat , Ahmed, Muktar Beshir , Akbari, Mohammad Esmaeil , AlAbdulKader, Assim M. , Alahdab, Fares , Alam, Shazia , Alamene, Genet Melak, Alene, Kefyalew Addis , Alipour, Vahid, Bakeshei, Fatemeh Allah, Almadi, Majid A. , Alsharif, Ubai , Alsowaidi, Shirina, Alvis‐Guzmán, Nelson , Amini, Saeed, Anbari, Zohreh , Anber, Nahla , Andrei, Cătălina Liliana , Anjomshoa, Mina, Ansari, Fereshteh, Ansariadi, Ansariadi , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Areri, Habtamu Abera , Artaman, Al, Asfaw, Ephrem Tsegay, Ashagre, Alebachew Fasil, Assadi, Reza , Atalay, Hagos Tasew , Ataro, Zerihun , Atique, Suleman , Ávila‐Burgos, Leticia , Avokpaho, Euripide , Awasthi, Ashish , Awoke, Nefsu , Quintanilla, Beatriz Paulina Ayala , Ayanore, Martin Amogre , Ayele, Henok Tadesse, Babaee, Ebrahim , Bacha, Umar, Badawi, Alaa, Bagherzadeh, Mojtaba , Bagli, Eleni , Balakrishnan, Senthilkumar , Bärnighausen, Till , Battista, Robert J., Behzadifar, Meysam, Belay, Yared Belete , Berfield, Kathleen, Berhane, Adugnaw , Bernabé, Eduardo , Beuran, Mircea , Bhakta, Nickhill , Bhattacharyya, Krittika , Biadgo, Belete , Bijani, Ali , Sayeed, Muhammad Shahdaat Bin , Bisignano, Catherine, Bitew, Helen , Bjørge, Tone , Bogale, Kassawmar Angaw , Bojia, Hunduma Amensisa, Borzì, Antonio Maria , Bou-Orm, Ibrahim R. , Brenner, Hermann , Brewer, Jerry D., Briko, Andrey , Брико, Н. И. , Bustamante-Teixeira, Maria Teresa , Butt, Zahid A , Carreras, Giulia , Carvalho, Félix , Castro, Clara , Castro, Franz , Catalá-López, Ferrán , Cerin, Ester , Chaiah, Yazan , Chanie, Wagaye Fentahun, Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chauhan, Neelima Singh, Chiang, Peggy Pei-Chia, Chichiabellu, Tesfaye Yitna , Chido‐Amajuoyi, Onyema Greg , Chimed‐Ochir, Odgerel , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Crowe, Christopher S. , Curado, María Paula , Dahlawi, Saad M A , Damiani, Giovanni , Darwish, Amira Hamed , Demissie, Birhanu Wondimeneh , Demoz, Gebre Teklemariam , Derakhshani, Afshin , Deribe, Kalkidan Solomon, Desai, Rupak , Desalegn, Beruk Berhanu , Dey, Subhojit , Dhimal, Meghnath , Díaz, Daniel , Dinberu, Mesfin Tadese, Djalalinia, Shirin, Drake, Thomas M , Dubljanin, Eleonora , Duken, Eyasu Ejeta, Effiong, Andem , Eftekhari, Aziz , El-Jaafary, Shaimaa I , El‐Khatib, Ziad , Elemineh, Demelash Abewa , Elkout, Hajer , Ellenbogen, Richard G. , Elsharkawy, Aisha , Emamian, Mohammad Hassan , Endalew, Daniel Adane , Endries, Aman Yesuf , Eshrati, Babak, Fadhil, Ibtihal , Farzadfar, Farshad , Fentahun, Netsanet , Fernandes, Eduarda , Feyissa, Garumma Tolu , Fischer, Florian , Fisher, James L. , Force, Lisa M , Freitas, Marisa , Fukumoto, Takeshi , Futran, Neal D. , Gallus, Silvano , Gankpé, Fortuné Gbètoho , Gayesa, Reta Tsegaye, Gebrehiwot, Tsegaye Tewelde , Gebremeskel, Gebreamlak Gebremedhn , Gedefaw, Getnet , Gelaw, Belayneh K., Geta, Birhanu, Getachew, Sefonias , Gezae, Kebede Embaye , Ghafourifard, Mansour , Ghajar, Alireza , Ghashghaee, Ahmad , Gholamian, Asadollah , Ginindza, Themba G. , Girmay, Alem, Gizaw, Muluken , Gomez, Ricardo Santiago , Gopalani, Sameer Vali , Gorini, Giuseppe , Goulart, Bárbara Niegia Garcia de , Grada, Ayman , Guerra, Maximiliano Ribeiro, Guimarães, André Luiz Sena , Gupta, Prakash C. , Hadkhale, Kishor , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hamidi, Samer , Hanfore, Lolemo Kelbiso , Hasankhani, Milad , Hasanzadeh, Amir , Hassen, Hamid Yimam , Hay, Simon I , Henok, Andualem , Herţeliu, Claudiu , Hoang, Chi Linh , Hole, Michael K., Hoogar, Praveen , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela, Hostiuc, Sorin , Househ, Mowafa , Hussen, Mohammedaman Mama, Ileanu, Bogdan Vasile , Ilić, Milena , Innos, Kaire , Irvani, Seyed Sina Naghibi , Iseh, Kufre Robert , Islam, Sheikh Mohammed Shariful , Balalami, Nader Jafari, Jafarinia, Morteza , Jahangiry, Leila , Jahanmehr, Nader , Jakovljević, Mihajlo, James, Spencer L , Jayaraman, Sudha , Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Jürisson, Mikk , Kamangar, Farin , Karimi, Narges , Karimian, Ansar , Kasaeian, Amir , Kasahun, Gebremicheal Gebreslassie , Kassa, Belete, Kassaw, Mesfin Wudu , Kaul, Anil, Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khalilarjmandi, Maryam, Khan, Ejaz Ahmad , Khan, Gulfaraz , Khang, Young-Ho, Khater, Amir M, Khayamzadeh, Maryam , Khazaee-Pool, Maryam , Khosravi, Mohammad Hossein , Khubchandani, Jagdish , Kianipour, Neda, Kim, Daniel , Kısa, Adnan , Kısa, Sezer , Komaki, Hamidreza , Krohn, Kristopher J, Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Vivek , Kuupiel, Desmond , Lad, Deepesh , Lake, Eyasu Alem , Lakew, Ayenew Molla , Lal, Dharmesh Kumar, Lami, Faris , Lan, Qing , Lasrado, Savita , Lazarus, Jeffrey V. , Leigh, James , Leshargie, Cheru Tesema , Liao, Yu , Limenih, Miteku Andualem , Listl, Stefan , Lopukhov, Platon D , Lunevičius, Raimundas , Madadin, Mohammed , Razek, Hassan Magdy Abd El , Majeed, Azeem , Manafi, Ali, Manafi, Navid , Manamo, Wondimu Ayele, Mantovani, LG , Martini, Santi , Mashamba-Thompson, Tivani P. , Massenburg, Benjamin B. , Maswabi, Motswadi Titus, McAlinden, Colm , Meheretu, Hailemariam Abiy Alemu , Mehrotra, Ravi , Meles, Gebrekiros Gebremichael , Meles, Hagazi Gebre , Melku, Mulugeta , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Merat, Shahin , Meretoja, Tuomo J , Miazgowski, Bartosz , Miazgowski, Tomasz , Mihretie, Kebadnew Mulatu M., Miller, Ted R. , Mills, Edward J , Mir, Seyed Mostafa , Mishra, Rashmi , Moazen, Babak , Mohammad, Dara K., Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Moslem, Mohammadian, Mahdi , Mohammadian-Hafshejani, Abdollah , Mohammadoo-Khorasani, Milad, Mohammed, Ammas Siraj , Mohammed, Jemal , Mohammed, Shafiu , Mohebi, Farnam , Mokdad, Ali H. , Monasta, Lorenzo , Moodley, Yoshan , Moosazadeh, Mahmood , Moossavi, Maryam , Moradi, Ghobad , Moradi-Joo, Mohammad , Moradpour, Farhad , Morawska, Lídia , Morgado-da-Costa, Joana, Mosapour, Abbas , Mousavi, Seyyed Meysam , Muche, Achenef Asmamaw , Muhammed, Oumer Sada , Musa, Jonah , Nabhan, Ashraf , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Nagel, Gabriele , Naik, Gurudatta , Nam, Hae‐Sung , Nazari, Javad , Negoi, Ionuţ , Neupane, Subas , Nggada, Haruna Asura , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nikniaz, Leila , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Nixon, Molly R, Nnaji, Chukwudi A , Shiadeh, Malihe Nourollahpour , Obsa, Mohammed Suleiman , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olagunju, Tinuke O , Oluwasanu, Mojisola , Omonisi, Abidemi , Onwujekwe, Obinna , Oommen, Anu Mary , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakpour, Amir H. , Pană, Adrian , Park, Eun‐Kee , Patel, Shanti, Patil, Snehal T, Pennini, Alyssa, Piccinelli, Cristiano, Pillay, Julian David , Pirestani, Majid , Postma, Maarten J. , Pourmalek, Farshad , Pourshams, Akram , Prakash, Swayam , Rabiee, Navid , Radfar, Amir , Rafiei, Alireza , Rahim, Fakher , Rahimi, Mahdi , Rahman, Muhammad Aziz , Rajati, Fatemeh , Rana, Saleem M., Raoofi, Samira , Rath, Goura Kishor, Rawaf, David Laith , Reiner, Robert C. , Renzaho, André M. N. , Rezapour, Aziz, Ribeiro, Ana Isabel , Ribeiro, Daniela , Roro, Elias Merdassa , Rostami, Ali , Saad, Ragy , Sabbagh, Parisa , Saddik, Basema , Safiri, Saeid , Salahshoor, Mohammad Reza , Salehi, Farkhonde , Salem, Hosni , Salem, Marwa Rashad , Salimzadeh, Hamideh , Salomon, Joshua A. , Samy, Abdallah M , Sanabria, Juan , Santric-Milicevic, Milena M , Sartorius, Benn , Sarveazad, Arash , Sathian, Brijesh , Satpathy, Maheswar , Savic, Miloje , Sawhney, Monika, Seyedmousavi, Seyedmojtaba , Shaahmadi, Faramarz , Shabaninejad, Hosein , Shahbaz, Mohammad , Shaikh, Masood Ali, Shamshirian, Amir , Shamsizadeh, Morteza , Sharafi, Zeinab , Sharifi, Ali , Sharifi, Hamid , Shirkoohi, Reza , Shukla, Sharvari , Si, Si , Siabani, Soraya , Silva, Diego Augusto Santos , Singh, Ambrish , Sisay, Solomon , Sobngwi, Eugène , Soofi, Moslem , Soriano, Joan B. , Stathopoulou, Vasiliki, Sufiyan, Mu’awiyyah Babale , Tabarés‐Seisdedos, Rafael , Tabuchi, Takahiro , Takahashi, Ken , Tarawneh, Mohammed Rasoul , Tassew, Segen Gebremeskel , Taymoori, Parvaneh , Temsah, Mohamad‐Hani , Temsah, Omar, Tesfay, Fisaha Haile , Teshale, Manaye Yihune, Tessema, Gizachew Assefa , Thapa, Subash , Tlaye, Kenean Getaneh , Topór-Mądry, Roman , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Khanh Bao , Tsadik, Afewerki Gebremeskel , Ullah, Irfan , Vaezi, Maryam, Pérez, Patricia Varona , Vidale, Simone , Violante, Francesco Saverio , Vollset, Stein Emil, Vos, Theo , Vosoughi, Kia , Vu, Giang Thu , Vujcic, Isidora S , Wabinga, Henry, Wachamo, Tesfahun Mulatu , Wagnew, Fasil Shiferaw, Waheed, Yasir , Weldegebreal, Fitsum , Weldesamuel, Girmay Teklay, Wijeratne, Tissa , Wonde, Tewodros Eshete , Workie, Hailemariam Mekonnen , Yadav, Rajaram , Yadegar, Abbas , Yadollahpour, Ali , Yaseri, Mehdi , Yazdi‐Feyzabadi, Vahid , Yeshaneh, Alex , Yimam, Mohammed , Yisma, Engida , Younis, Mustafa Z , Zadnik, Vesna, Moghadam, Telma Zahirian , Zandian, Hamed , Zangeneh, Alireza , Zaki, Leila , Zendehdel, Kazem , Zenebe, Zerihun Menlkalew, Zewale, Taye Abuhay , Ziapour, Arash , Zodpey, Sanjay , Murray, Christopher J L , Topór‐Mądry, Roman , Deribe, Kebede , Teklay, Girmay , Wijeratne, T , Kumar, Vivek , Lazarus, Jeffrey V , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Abd-Allah, Foad , Abdel-Rahman, Omar Mohammed , Abdollahpour, Ibrahim , Abu-Raddad, Laith Jamal , Ahmadian, Elham , Ahmadpour, Ehsan , Akinyemiju, Tomi , Al‐Aly, Ziyad , Alemnew, Birhan , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Amini, Erfan , Amini, Saeed, Amoako, Yaw Ampem , Arab-Zozani, Morteza , Asayesh, Hamid , Fasil, Alebachew , Ataeinia, Bahar , Ausloos, Marcel , Balouchi, Abbas , Behzadifar, Masoud , Behzadifar, Meysam, Bekele, Bayu Begashaw , Belayneh, Yaschilal Muche , Birungi, Charles , Bleyer, Archie , Bosetti, Cristina , Carrero, Juan Jesús , Chaturvedi, Pankaj , Chehrazi, Mohammad , Constantin, María Magdalena , Crocetti, Emanuele , Daryani, Ahmad , Neves, José das , Demeke, Feleke Mekonnen , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Deribe, Kalkidan Solomon, Desta, Melaku , Dharmaratne, Samath Dhamminda , Doku, David Teye , Dubey, Manisha , Ebrahimi, Hedyeh , Sayed, Iman El , Zaki, Maysaa El Sayed , Adane, Daniel, Omrani, Vahid Fallah , Faramarzi, Mahbobeh , Farhangi, Mahdieh Abbasalizad , Farioli, Andrea , Filip, Irina , Foroutan, Masoud , Tsegaye, Reta , Gelaw, Belayneh K., Gill, Paramjit Singh , Gupta, Rahul, Haro, Josep María , Hay, Roderick J. , Henry, Nathaniel J , Hidru, Hagos Degefa , Horita, Nobuyuki , Hosgood, H. Dean, Hostiuc, Mihaela, Hussen, Mohammedaman Mama, Islami, Farhad , Jahani, Mohammad Ali , Jakovljević, Mihajlo , Javanbakht, Mehdi , Jee, Sun Ha , Jenabi, Ensiyeh , Jonnagaddala, Jitendra, Jungari, Suresh Banayya , Kabir, Ali , Karch, André , Kassa, Tesfaye , Kerbo, Amene Abebe , Khang, Young-Ho, Khatab, Khaled , Khazaei, Salman , Khoja, Abdullah T , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Vecchia, Carlo La , Lal, Dharmesh Kumar, Lauriola, Paolo , Lopez, Alan D , Magdeldin, Sameh , Maleki, Afshin , Malekzadeh, Reza , Manamo, Wondimu Ayele, Mansourian, Morteza , Mansournia, Mohammad Alì , Maroufizadeh, Saman , Mathur, Manu Raj , McKee, Martin , Mehta, Varshil , Meier, Toni , Melaku, Yohannes Adama , Melese, Addisu Dagnaw , Meštrović, Tomislav , Mulatu, Kebadnew , Mirzaei, Hamed , Mirzaei, Hamid Reza , Mohammad, Dara K., Darwesh, Aso Mohammad , Mohammadbeigi, Abolfazl , Mohammadi, Hiwa , Mohammadi, Moslem, Mohammadpourhodki, Reza , Moradi‐Lakeh, Maziar , Morisaki, Naho , Morrison, Shane D. , Nahvijou, Azin , Najafi, Farid , Naldi, Luigi , Nasiri, Naser , Newcomb, Polly A. , Nojomi, Marzieh , Nosratnejad, Shirin , Oh, In‐Hwan , Oren, Eyal , Ota, Erika , Owolabi, Mayowa , Parsian, Hadi , Pashaei, Tahereh , Pereira, David M. , Pishgar, Farhad , Pourjafar, Hadi , Prasad, Narayan , Qorbani, Mostafa , Rabiee, Mohammad , Rana, Saleem M., Rawaf, Salman , Rezaei, Nima , Ronfani, Luca , Roshandel, Gholamreza , Saad, Ragy , Sabbagh, Parisa, Sabour, Siamak , Sahebkar, Amirhossein , Sayyah, Mehdi , Schneider, Ione Jayce Ceola , Schöttker, Ben , Šekerija, Mario , Sepanlou, Sadaf Ghajarieh , Sepehrimanesh, Masood , Sharafi, Heidar , Sharif, Mehdi , Sharma, Rajesh , Sheikh, Aziz , Silveira, Dayane Gabriele Alves , Singh, Jasvinder A. , Sitas, Freddy , Tamtaji, Omid Reza , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Teshale, Manaye Yihune, Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Vacante, Marco , Vaezi, Maryam, Veisani, Yousef , Vlassov, Vasily , Vollset, Stein Emil, Wagnew, Fasil , Wondafrash, Dawit Zewdu , Wondmieneh, Adam Belay , Yimer, Ebrahim M , Yonemoto, Naohiro , Yousefi, Bahman , Yousefifard, Mahmoud , Yu, Chuanhua , Zabeh, Erfan , Zaidi, Zoubida , Zamani, Mohammad , Olagunju, Andrew T , Bhakta, Nickhill , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

JAMA Oncology | September 27, 2019 | Volume: 5 | Issue: 12 | Pages: 1749

10.1001/jamaoncol.2019.2996 | PMID 31560378 Get It